HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bone marrow pilot study comparing BMT to peripheral blood stem cell transplants to begin.

Executive Summary

BONE MARROW COMPARISON TO PERIPHERAL BLOOD STEM CELL TRANSPLANTATION through large-scale trials may begin in two years if a pilot study by the National Marrow Donor Program is successful. A clinical trial, slated to begin in late September, will compare secondary donation of allogeneic PBSCs collected by apheresis to standard marrow donation. PBSCs will be stimulated with recombinant granulocyte-colony stimulating factor (Amgen's Neupogen, filgrastim).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026656

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel